造血干细胞移植预处理药物白消安的群体药动学研究进展

Research advances in population pharmacokinetics of pre-treatment drug busulfan for hematopoietic stem cell transplantation

白消安在临床中常用于异基因造血干细胞移植前预处理方案,然而,白消安体内吸收、分布、代谢、排泄在个体间差异较大,尤其在代谢过程中受到年龄、体重、基因多态性、昼夜节律和药物相互作用等多种因素影响,为临床预测白消安剂量增加了难度。研究表明,使用群体药动学(PPK)模型能良好地预测白消安的血药浓度,因此通过查阅国内、外相关文献,对相关文献进行分析、归纳、总结,为开展中国各群体中PPK研究提供思路,有助于提高白消安临床疗效、降低移植后并发症风险。

Busulfan is commonly employed as a pre-treatment regimen prior to allogeneic hematopoietic stem cell transplantation.However, great individual variations are existed in its absorption, distribution, metabolism and excretion.The influencing factors include age, weight, gene polymorphism, circadian rhythm and drug interaction during metabolism.Thus it is rather difficult to predict its clinical dose.Researches have shown that using a model of population pharmacokinetics(PPK)could better predict its concentration.Here the relevant domestic and foreign literature reports were collated for providing rationales for conducting PPK studies in China.The goal is to improve the clinical efficacy of Busulfan and reduce its risks of complications after transplantation.